TK1 and malignant peripheral nerve sheath tumor: Four of these nine compounds were selected for validation: BI2536 was selected as a targeted kinase inhibitor, floxuridine was selected due to its association with thymidine kinase 1 (TK1), previously identified as a prognostic biomarker (Kolberg et al., 2015), while methotrexate and pemetrexed were selected for their differential response in MPNST cell lines.